timothy sykes logo
Recursion Pharmaceuticals Falls 10% as Broad Market Sells Off Thumbnail

Recursion Pharmaceuticals Falls 10% as Broad Market Sells Off

TIMOTHY SYKES•UPDATED NOV. 20, 2026, 10:25 AM ET

Recursion Pharmaceuticals fell 10% as broad market selling hit demand for companies betting on future drug breakthroughs.

RXRX Candlestick Chart

Why Recursion Stock Fell 10% Today

Today, a broad market selloff pulled Recursion Pharmaceuticals Inc. (NASDAQ: RXRX) down 10% to $2.46 this afternoon. Broad selling reduces what investors will pay for businesses whose value rests on future commercial success.

What Recursion Pharmaceuticals Inc. Does

Recursion uses artificial intelligence, computer models trained on experimental data, to discover and develop potential medicines. Its drugs still need human testing and regulatory approval before they can generate product sales.

Recursion Falls Further Than Biotech Fund

the SPDR S&P Biotech ETF (XBI), a traded basket of biotech stocks used here for comparison, was down 3%. Recursion’s uncertain future drug earnings make its shares vulnerable when investors accept less risk. That helps explain its larger decline, without implying that current revenue fell today.

Quick Financial Overview

Recursion is a small-cap, a smaller public company with $1.53B in stock-market value, and remains unprofitable. It held $549.9M in cash and cash equivalents, meaning cash the company can spend, as of September 30, 2026. That covers about twenty-one months at the latest quarterly spending rate.

Recursion Revenue and Development Costs

Quarterly revenue was $18.1M, alongside a net loss of $119.0M. Running the business consumed $77.4M in cash during the quarter. That spending continues while potential medicines move through testing.

Recursion Share Offering History

Recursion’s recent documents describing a potential share sale show fundraising activity. Issuing new shares reduces each existing owner’s percentage stake. A lower stock price means more shares would be needed to raise the same cash.

Recursion Stock Returns Near Its Annual Low

RXRX is down 18% over six months from around $3.00, placing today’s decline within a longer retreat toward its annual low. A brief recovery did not reverse that trend. For Recursion, the last daily move this large was eleven sessions ago.

Trading Perspective

The first recovery hurdle is around $2.75, where a return would recover today’s opening loss. The annual high in the low $5s remains a distant ceiling, not a near-term forecast.


Recursion Drug Trial Design Progress

The decline comes after U.S. drug regulators agreed with the design of a later round of human testing for its experimental drug REC-4881. It targets an inherited condition that causes digestive-tract growths and raises cancer risk. The study is on track to begin in the second half of 2027; design agreement does not establish that the treatment works.

Recursion Investor Conference on November 30

Recursion is scheduled to participate in an investor conference on Monday, November 30, 2026. That gives management another chance to discuss development plans before the major study begins.

Conclusion

The upcoming investor conference could help holders judge whether development spending matches the planned trial schedule. Clearer milestones would make progress easier to assess, while little new detail would leave investors waiting for clinical evidence. Recursion’s funding covers the wait, so the immediate distinction is between market pressure and the longer task of proving its drugs work.

This is stock news, not investment advice. Timothy Sykes News delivers real-time stock market news focused on key catalysts driving short-term price movements. Our content is tailored for active traders and investors seeking to capitalize on rapid price fluctuations, particularly in volatile sectors like penny stocks. Readers come to us for detailed coverage on earnings reports, mergers, FDA approvals, new contracts, and unusual trading volumes that can trigger significant short-term price action. Some users utilize our news to explain sudden stock movements, while others rely on it for diligent research into potential investment opportunities.

Dive deeper into the world of trading with Timothy Sykes, renowned for his expertise in penny stocks. Explore his top picks and discover the strategies that have propelled him to success with these articles:

Once you’ve got some stocks on watch, elevate your trading game with StocksToTrade the ultimate platform for traders. With specialized tools for swing and day trading, StocksToTrade will guide you through the market’s twists and turns.
Dig into StocksToTrade’s watchlists here:


How much has this post helped you?



Leave a reply

* Results are not typical and will vary from person to person. Making money trading stocks takes time, dedication, and hard work. There are inherent risks involved with investing in the stock market, including the loss of your investment. Past performance in the market is not indicative of future results. Any investment is at your own risk. See Terms of Service here

The available research on day trading suggests that most active traders lose money. Fees and overtrading are major contributors to these losses.

A 2000 study called “Trading is Hazardous to Your Wealth: The Common Stock Investment Performance of Individual Investors” evaluated 66,465 U.S. households that held stocks from 1991 to 1996. The households that traded most averaged an 11.4% annual return during a period where the overall market gained 17.9%. These lower returns were attributed to overconfidence.

A 2014 paper (revised 2019) titled “Learning Fast or Slow?” analyzed the complete transaction history of the Taiwan Stock Exchange between 1992 and 2006. It looked at the ongoing performance of day traders in this sample, and found that 97% of day traders can expect to lose money from trading, and more than 90% of all day trading volume can be traced to investors who predictably lose money. Additionally, it tied the behavior of gamblers and drivers who get more speeding tickets to overtrading, and cited studies showing that legalized gambling has an inverse effect on trading volume.

A 2019 research study (revised 2020) called “Day Trading for a Living?” observed 19,646 Brazilian futures contract traders who started day trading from 2013 to 2015, and recorded two years of their trading activity. The study authors found that 97% of traders with more than 300 days actively trading lost money, and only 1.1% earned more than the Brazilian minimum wage ($16 USD per day). They hypothesized that the greater returns shown in previous studies did not differentiate between frequent day traders and those who traded rarely, and that more frequent trading activity decreases the chance of profitability.

These studies show the wide variance of the available data on day trading profitability. One thing that seems clear from the research is that most day traders lose money .

Millionaire Media 66 W Flagler St. Ste. 900 Miami, FL 33130 United States (888) 878-3621 This is for information purposes only as Millionaire Media LLC nor Timothy Sykes is registered as a securities broker-dealer or an investment adviser. No information herein is intended as securities brokerage, investment, tax, accounting or legal advice, as an offer or solicitation of an offer to sell or buy, or as an endorsement, recommendation or sponsorship of any company, security or fund. Millionaire Media LLC and Timothy Sykes cannot and does not assess, verify or guarantee the adequacy, accuracy or completeness of any information, the suitability or profitability of any particular investment, or the potential value of any investment or informational source. The reader bears responsibility for his/her own investment research and decisions, should seek the advice of a qualified securities professional before making any investment, and investigate and fully understand any and all risks before investing. Millionaire Media LLC and Timothy Sykes in no way warrants the solvency, financial condition, or investment advisability of any of the securities mentioned in communications or websites. In addition, Millionaire Media LLC and Timothy Sykes accepts no liability whatsoever for any direct or consequential loss arising from any use of this information. This information is not intended to be used as the sole basis of any investment decision, nor should it be construed as advice designed to meet the investment needs of any particular investor. Past performance is not necessarily indicative of future returns.

Citations for Disclaimer

Barber, Brad M. and Odean, Terrance, Trading is Hazardous to Your Wealth: The Common Stock Investment Performance of Individual Investors. Available at SSRN: “Day Trading for a Living?”

Barber, Brad M. and Lee, Yi-Tsung and Liu, Yu-Jane and Odean, Terrance and Zhang, Ke, Learning Fast or Slow? (May 28, 2019). Forthcoming: Review of Asset Pricing Studies, Available at SSRN: “https://ssrn.com/abstract=2535636”

Chague, Fernando and De-Losso, Rodrigo and Giovannetti, Bruno, Day Trading for a Living? (June 11, 2020). Available at SSRN: “https://ssrn.com/abstract=3423101”